Prime Therapeutics, June 2025 — analysis of 16.5 million covered lives.
The most effective obesity drugs ever developed have a retention problem.
GLP-1 receptor agonists — Ozempic, Wegovy, Mounjaro, Zepbound — are the most important obesity treatment in decades. In clinical trials, patients lost 15–20% of their body weight. For millions of people, these drugs delivered what no diet, exercise program, or previous medication ever could.
This is not an article about whether GLP-1 drugs work. They work.
This is about what happens next.
What a typical GLP-1 patient’s weight trajectory actually looks like — including what happens after they stop.
The green line is the promise. The red line is the reality for the vast majority. Of patients who start GLP-1 therapy for obesity, 47–65% discontinue within the first year alone. JAMA Network Open, Jan 2025, n=125,474
By year three, only 8.1% are still taking their medication — meaning 91.9% have stopped. Prime Therapeutics, Jun 2025, n=16.5M covered lives
The reasons 92% of patients discontinue GLP-1 therapy — from an analysis of 78,781 patients.
After stopping GLP-1 medication, weight regain is 4× faster than after behavioral interventions — regardless of how much weight was initially lost.
GLP-1 therapy is designed to be taken indefinitely. Select a pricing tier to see what that means over time.
And if you’re in the 92% who stop, you’ll regain the weight within 1.7 years.
Weight loss curve based on STEP 1 trial data (semaglutide 2.4 mg). Regain rate: 0.8 kg/month for semaglutide/tirzepatide (BMJ, West et al., Jan 2026). This is a population-level projection, not individual medical advice.